Noninvasive Electrical Stimulator as a Pain Control Treatment Post-ureteroscopy
Noninvasive Electrical Stimulator as an Adjunct for Pain Control After Ureteroscopic Stone Management
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Conti
- Phone Number: (650) 723-3391
- Email: sconti@stanford.edu
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients undergoing standard of care ureteroscopy and laser lithotripsy for urinary stone disease
- Patients receiving a stent following their ureteroscopy and laser lithotripsy
Exclusion Criteria:
- Children
- Pregnant patients
- Patients unable to answer pain questionnaire
- Patients undergoing PCNL
- Patients being treated for Urologic malignancy with ureteroscopy
- Patients who require long term or chronic ureteral stent management
- Patient with implantable stimulators
- Patient with epilepsy
- Patients undergoing laser lithotripsy without stent placement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Standard care
Participants will follow standard care until the ureteral stent is removed
|
|
|
Experimental: TENS device
Participants will use the TENS device until the ureteral stent is removed
|
TENS device used four times a day for 60 minutes each time
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain on 11-point Visual Analog Score Scale (VAS)
Time Frame: Assessed daily until removal of stent, approximately 3-10 days after placement
|
Cumulative average pain score using an 11-point VAS. The VAS is a validated tool widely used to assess pain intensity. Possible score ranges:
|
Assessed daily until removal of stent, approximately 3-10 days after placement
|
|
Difference in Pain on 11-point Visual Analog Score Scale (VAS)
Time Frame: Assessed daily until removal of stent, approximately 3-10 days after placement
|
Cumulative average difference in pain score using an 11-point VAS. The VAS is a validated tool widely used to assess pain intensity. Possible score ranges:
|
Assessed daily until removal of stent, approximately 3-10 days after placement
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Opioid Consumption
Time Frame: Until stent removal (up to 10 days)
|
Consumption in morphine milligram equivalents (MME), based on patient-self-report in Daily Symptom Questionnaire.
|
Until stent removal (up to 10 days)
|
|
Difference in Total Opioid Consumption
Time Frame: Until stent removal (up to 10 days)
|
Consumption (in MME), based on patient-self-report in Daily Symptom Questionnaire.
|
Until stent removal (up to 10 days)
|
|
Ureteral Stent Discomfort Test (USDT) Scale Score
Time Frame: Assessed at removal of stent, approximately 3-10 days after placement
|
Overall score scale:0 to 61 points; subdomain scales: urinary symptoms: 0 to 30; pain: 0 to 6: daily life: 0 to 5; sexual life: 0 to 5; medical care/analgesic use: 0 to 10; and overall quality of life: 0 to 5. Subscale scores are totaled to calculate the overall score.
Higher scores correspond to more severe symptoms for the overall score and all subscale scores.
|
Assessed at removal of stent, approximately 3-10 days after placement
|
|
Patient Satisfaction Survey
Time Frame: End of study (day 3 to 10)
|
Participants were asked if they would prefer using TENS over pain medication during a pain episode, and whether they would consider using TENS over pain medication in the future.
This outcome was assessed only in participants who were randomized to the TENS device group.
|
End of study (day 3 to 10)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Simon Conti, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Male Urogenital Diseases
- Pathological Conditions, Anatomical
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urolithiasis
- Urinary Calculi
- Ureteral Diseases
- Kidney Calculi
- Nephrolithiasis
- Ureteral Calculi
- Ureterolithiasis
- Calculi
Other Study ID Numbers
Other Study ID Numbers
- IRB-62416
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.